**Background of CCT2 Antibody**
The CCT2 (Chaperonin Containing TCP-1 subunit 2) antibody is a research tool targeting subunit 2 of the chaperonin-containing TCP-1 (CCT) complex, a molecular chaperone critical for folding cytoskeletal proteins like actin and tubulin. The CCT complex, composed of eight distinct subunits (CCT1-8), assists in ATP-dependent folding of nascent polypeptides, ensuring proper protein conformation and cellular function.
CCT2-specific antibodies are widely used to study the expression, localization, and functional roles of CCT2 in cellular processes, including cell cycle regulation, stress responses, and signal transduction. Dysregulation of CCT2 has been linked to cancers, neurodegenerative diseases, and developmental disorders, making it a potential biomarker or therapeutic target. These antibodies are employed in techniques like Western blotting, immunofluorescence, and immunohistochemistry to assess protein levels in tissues or cultured cells.
Recent studies highlight CCT2's involvement in tumor progression, where its overexpression correlates with poor prognosis. Additionally, CCT2 interacts with disease-related misfolded proteins (e.g., α-synuclein in Parkinson’s), suggesting roles in proteostasis. Researchers also explore its response to cellular stress, such as heat shock or proteotoxic conditions, where CCT2 expression may be upregulated. Validating antibody specificity remains crucial, given the structural similarities among CCT subunits. Overall, CCT2 antibodies are vital for elucidating chaperonin biology and its implications in health and disease.